Stephanie Davis
Stock Analyst at Barclays
(0.97)
# 3,580
Out of 4,711 analysts
101
Total ratings
29.23%
Success rate
-20.15%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $4.91 | +1.83% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $57.83 | +29.69% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.29 | -3.98% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.44 | +35.14% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $11.41 | +66.52% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $227.69 | +27.37% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $21.76 | +10.29% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $118.28 | +12.45% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $44.98 | +28.95% | 2 | Oct 31, 2024 | |
| TALK Talkspace | Maintains: Equal-Weight | $2 → $3 | $2.98 | +0.67% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $154 → $168 | $153.10 | +9.73% | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $1.34 | -44.03% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5.5 → $5 | $3.48 | +43.68% | 10 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $228.61 | +8.92% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $36.82 | -34.82% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $25.16 | +15.26% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $9.44 | +260.17% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $14.34 | +137.10% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $224.15 | +3.95% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $7.09 | +139.77% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $94.95 | -19.96% | 5 | Jun 7, 2022 |
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.91
Upside: +1.83%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $57.83
Upside: +29.69%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.29
Upside: -3.98%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.44
Upside: +35.14%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $11.41
Upside: +66.52%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $227.69
Upside: +27.37%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.76
Upside: +10.29%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $118.28
Upside: +12.45%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $44.98
Upside: +28.95%
Talkspace
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.98
Upside: +0.67%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $154 → $168
Current: $153.10
Upside: +9.73%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $1.34
Upside: -44.03%
Oct 9, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $5
Current: $3.48
Upside: +43.68%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $228.61
Upside: +8.92%
Jul 2, 2024
Initiates: Overweight
Price Target: $24
Current: $36.82
Upside: -34.82%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $25.16
Upside: +15.26%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $9.44
Upside: +260.17%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $14.34
Upside: +137.10%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $224.15
Upside: +3.95%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $7.09
Upside: +139.77%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $94.95
Upside: -19.96%